Trial Profile
An Exploratory Study Of Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation Determined By Different Molecular Diagnostic Methods
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jul 2018 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified July 2016).
- 20 Jul 2016 Planned End Date changed from 1 Dec 2014 to 1 Mar 2017.
- 20 Jul 2016 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2016.